The U.S. Patent and Trademark Office (USPTO) has recently implemented new policies aimed at preserving patents from legal challenges, a move intended to bolster innovation protection. However, critics, including some pharmaceutical companies, argue that these changes may hinder the validation process of patents, ultimately complicating the pathway for lower-cost medicines to reach consumers. This situation raises concerns about the potential contradiction of the Trump administration’s goals regarding drug pricing and accessibility, particularly in light of the agency’s inter partes review (IPR) procedures, which have historically been crucial in resolving patent disputes.
In a significant development for global health, Novartis has announced a promising new malaria treatment, GanLum, which has shown to cure over 99% of malaria cases in late-stage trials. This marks the first major advancement in malaria medication in over 25 years, a critical need as the disease continues to claim hundreds of thousands of children’s lives annually. The drug not only addresses current malaria cases but also aims to mitigate the rising threat of drug resistance in sub-Saharan Africa, thus representing a vital addition to the therapeutic arsenal against this persistent global health challenge.
Continue to STAT+ to read the full story…
Open the full market picture for your next decision →
